FindTrial
Sign In

Iomab-B

DRUG2 trials

Sponsors

Actinium Pharmaceuticals, University of Texas Southwestern Medical Center

Conditions

AMLAcute Myelogenous LeukemiaAcute Myeloid LeukemiaBone Marrow TransplantDiffuse Large B Cell LymphomaLeukemia, Acute MyelogenousLeukemia, Acute MyeloidLeukemia, Myeloid, Acute

Phase 1

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
RecruitingNCT06768905
University of Texas Southwestern Medical CenterDiffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma
Start: 2025-04-25End: 2030-05-01Target: 30Updated: 2026-05-08

Phase 3

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Active, not recruitingNCT02665065
Actinium PharmaceuticalsAcute Myelogenous Leukemia, Acute Myeloid Leukemia, AML +6
Start: 2016-06-30End: 2026-12-31Updated: 2023-07-19

Related Papers

Randomized Phase III SIERRA Trial of <sup>131</sup> I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
Journal of Clinical Oncology2024-09-1911 citations
131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML
Blood2023-11-022 citations
High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML
Blood2023-11-022 citations
131I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors
Blood2023-11-021 citations
S248: SIERRA TRIAL RESULTS WITH A TARGETED RADIOTHERAPY, IOMAB-B, A MYELOABLATIVE CONDITIONING WITH REDUCED INTENSITY TOLERABILITY YIELDS HIGH CR, LONG TERM SURVIVAL IN HSCT INELIGIBLE ACTIVE R/R AML
HemaSphere2023-08-017 citations
Where do we stand with radioimmunotherapy for acute myeloid leukemia?
2022-03-3112 citations
Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies
Blood2021-11-059 citations
Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered
Blood2020-11-049 citations
High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Blood2020-11-047 citations
Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial
Biology of Blood and Marrow Transplantation2020-01-232 citations
Antibodies to watch in 2020.
2020-01-01328 citations
Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial
Blood2019-11-134 citations
Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine (<sup>131</sup>I) apamistamab [Iomab-B] radioimmunotherapy in the phase III SIERRA trial.
Journal of Clinical Oncology2019-05-207 citations
Targeted Conditioning of Iomab-B (131I-anti-CD45) Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Relapsed or Refractory Acute Myeloid Leukemia (AML): Preliminary Feasibility and Safety Results from the Prospective, Randomized Phase 3 Sierra Trial
Blood2018-11-2911 citations